ADIA Nutrition Inc Appoints First Doctor of Its Medical Division
ADIA Nutrition Inc Appoints First Doctor of Its Medical Division
Winter Park, Florida--(Newsfile Corp. - August 20, 2024) - ADIA Nutrition Inc. (OTC Pink: ADIA) has appointed Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients.
佛罗里达州温特帕克--(Newsfile Corp.,2024年8月20日)——ADIA Nutrition Inc.(场外交易链接:ADIA)已任命莫妮卡·谢尔博士为其医疗部主任之一,她将在帮助制定该公司针对多发性硬化(MS)患者的自体造血干细胞移植(AHSCT)计划的政策和程序方面发挥重要作用。
Dr. Monica Sher
莫妮卡·谢尔博士
Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
经过全面的搜索和选择过程,谢尔博士之所以被选中,是因为她在医学领域的丰富经验和专业知识。凭借内科背景和对健康和保健的热情,她非常适合协助领导 ADIA Nutrition 推进多发性硬化症的 aHSCT 疗法
Dr. Sher expressed her excitement about joining ADIA Nutrition Inc., stating, "I am honored to become one of the directors of ADIA's Medical Division. This opportunity aligns perfectly with my passion for improving the lives of patients through stem cell therapy and cutting-edge medical interventions like aHSCT. I look forward to collaborating with the talented team at ADIA Nutrition to drive innovation and deliver exceptional care to our patients."
谢尔博士对加入ADIA营养公司表示兴奋,她说:“我很荣幸成为ADIA医疗部门的负责人之一。这个机会完全符合我对通过干细胞疗法和AHSCT等尖端医疗干预措施改善患者生活的热情。我期待与ADIA Nutrition的才华横溢的团队合作,推动创新并为我们的患者提供卓越的护理。”
Larry Powalisz, CEO of ADIA Nutrition Inc., welcomed Dr. Sher to the team, saying, "We are thrilled to have Dr. Sher join us. Her knowledge and expertise in internal medicine and commitment to advancing Stem Cell treatment for MS through aHSCT will be invaluable as we continue to grow and expand our medical division. We are confident that Dr. Sher will be a great asset to our company and will aid ADIA in providing the highest level of care to our patients."
ADIA Nutrition Inc. 首席执行官拉里·波瓦利斯欢迎谢尔博士加入团队,他说:“我们很高兴谢尔博士加入我们。随着我们继续发展和扩大医疗部门,她在内科医学方面的知识和专业知识以及对通过AHSCT推进多发性硬化症干细胞治疗的承诺将是无价的。我们相信,谢尔博士将成为我们公司的宝贵资产,并将帮助ADIA为我们的患者提供最高水平的护理。”
In a unique arrangement, Dr. Sher has agreed to receive equity in the company in exchange for her directorial role, opting not to receive a salary. Instead, she will be compensated per each procedure, highlighting her dedication to the company's success and the advancement of medical treatment for MS.
在一项独特的安排中,谢尔博士同意获得公司的股权以换取她的董事职位,她选择不领取工资。取而代之的是,她将按每项手术获得报酬,这凸显了她对公司成功和推进多发性硬化症治疗的奉献精神
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
如需媒体咨询或了解更多信息,请通过 ceo@adiamed.com 或 321-788-0850 与 Larry Powalisz 联系。
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
关于 ADIA Nutrition Inc.:
Adia Nutrition Inc. 是一家上市公司(场外交易代码:ADIA),致力于革新医疗保健和补充剂。该公司专注于创新和质量,建立了两个关键部门:提供优质有机补充剂的补充剂部门和专门从事多发性硬化症(MS)自体造血干细胞移植(AHSCT)治疗的医疗部门。通过这些部门,Adia Nutrition Inc. 致力于通过满足营养需求和开创性的药物治疗,让个人过上最美好的生活。
Website:
Website:
Website:
Website:
Twitter (X): @ADIA_Nutrition
网站:
网站:
网站:
网站:
推特 (X):@ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
安全港:本新闻稿包含1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的前瞻性陈述。这些前瞻性陈述基于管理层当前的计划和预期,存在一些不确定性和风险,可能会对公司当前的计划和预期以及未来的经营业绩和财务状况产生重大影响。在公司向美国证券交易委员会和场外交易市场公司场外交易披露和新闻服务提交的报告和其他文件中,可以找到更广泛的风险和因素清单,这些风险和因素可能影响公司的业务前景并导致实际业绩与前瞻性陈述中描述的结果存在重大差异。由于新信息、未来事件或其他原因,公司没有义务公开更新或修改任何前瞻性陈述。